Latest News

NNOX earnings call for the period ending December 31, 2024.

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel). 

The spot level of VIX is truly inverted vis-à-vis the futures, but the overall curve is largely flattish.

ETFs classified as Equity U.S. held 26.83% of the overall assets under management at the end of December 2024.

Sabra Healthcare REIT stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 78 to 82 Monday.

Investors should prepare for a 2008-style crisis.Benzinga warns of potential economic crisis predicted by Peter Schiff in 2008. Tariffs, rising interest rates, misguided Fed policy may cause trouble.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

In a welcome move, Stryker stock saw its Relative Strength Rating improve to 72 on Monday, up from 69 a day earlier.

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.

In today's session, these stocks are experiencing unusual volume.

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Allspring Global Investments launched two new actively managed ETFs (AGR, ASLV) to provide investors with access to mispriced stocks and value ideas.